Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2015 Oct 20

PMID 26478893

Citations 101

Authors

Daniel I S Rosenbloom

Oliver Elliott

Alison L Hill

Timothy J Henrich

Janet M Siliciano

Robert F Siliciano

Affiliations

Soon will be listed here.

Abstract

Limiting dilution assays are widely used in infectious disease research. These assays are crucial for current human immunodeficiency virus (HIV)-1 cure research in particular. In this study, we offer new tools to help investigators design and analyze dilution assays based on their specific research needs. Limiting dilution assays are commonly used to measure the extent of infection, and in the context of HIV they represent an essential tool for studying latency and potential curative strategies. Yet standard assay designs may not discern whether an intervention reduces an already miniscule latent infection. This review addresses challenges arising in this setting and in the general use of dilution assays. We illustrate the major statistical method for estimating frequency of infectious units from assay results, and we offer an online tool for computing this estimate. We recommend a procedure for customizing assay design to achieve desired sensitivity and precision goals, subject to experimental constraints. We consider experiments in which no viral outgrowth is observed and explain how using alternatives to viral outgrowth may make measurement of HIV latency more efficient. Finally, we discuss how biological complications, such as probabilistic growth of small infections, alter interpretations of experimental results.

Citing Articles

HIV-1 diversity in viral reservoirs obtained from circulating T-cell subsets during early ART and beyond.

Zhang Y, Otte F, Stoeckle M, Thielen A, Daumer M, Kaiser R PLoS Pathog. 2024; 20(9):e1012526.

PMID: 39292732 PMC: 11410260. DOI: 10.1371/journal.ppat.1012526.

Dual role of circulating and mucosal Vδ1 T cells in the control of and contribution to persistent HIV-1 infection.

Mann B, Sanz M, Clohosey M, Langlands K, Chitrakar A, Moreno C Res Sq. 2024; .

PMID: 39149467 PMC: 11326412. DOI: 10.21203/rs.3.rs-4784403/v1.

Specific quantification of inducible HIV-1 reservoir by RT-LAMP.

Hossain T, Lungu C, de Schrijver S, Kuali M, Crespo R, Reddy N Commun Med (Lond). 2024; 4(1):123.

PMID: 38918506 PMC: 11199587. DOI: 10.1038/s43856-024-00553-4.

CD8+ cells and small viral reservoirs facilitate post-ART control of SIV replication in M3+ Mauritian cynomolgus macaques initiated on ART two weeks post-infection.

Harwood O, Matschke L, Moriarty R, Balgeman A, Weaver A, Ellis-Connell A PLoS Pathog. 2023; 19(9):e1011676.

PMID: 37747933 PMC: 10553806. DOI: 10.1371/journal.ppat.1011676.

The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy.

McMyn N, Varriale J, Fray E, Zitzmann C, MacLeod H, Lai J J Clin Invest. 2023; 133(17).

PMID: 37463049 PMC: 10471168. DOI: 10.1172/JCI171554.

References

Yukl S, Boritz E, Busch M, Bentsen C, Chun T, Douek D . Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 2013; 9(5):e1003347. PMC: 3649997. DOI: 10.1371/journal.ppat.1003347. View

Laird G, Eisele E, Rabi S, Lai J, Chioma S, Blankson J . Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 2013; 9(5):e1003398. PMC: 3667757. DOI: 10.1371/journal.ppat.1003398. View

Besnier C, Takeuchi Y, Towers G . Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A. 2002; 99(18):11920-5. PMC: 129369. DOI: 10.1073/pnas.172384599. View

Siliciano J, Kajdas J, Finzi D, Quinn T, Chadwick K, Margolick J . Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003; 9(6):727-8. DOI: 10.1038/nm880. View

Rouzine I, Razooky B, Weinberger L . Stochastic variability in HIV affects viral eradication. Proc Natl Acad Sci U S A. 2014; 111(37):13251-2. PMC: 4169906. DOI: 10.1073/pnas.1413362111. View

Bullen C, Laird G, Durand C, Siliciano J, Siliciano R . New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014; 20(4):425-9. PMC: 3981911. DOI: 10.1038/nm.3489. View

Farber D, Yudanin N, Restifo N . Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2013; 14(1):24-35. PMC: 4032067. DOI: 10.1038/nri3567. View

Archin N, Liberty A, Kashuba A, Choudhary S, Kuruc J, Crooks A . Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012; 487(7408):482-5. PMC: 3704185. DOI: 10.1038/nature11286. View

Siliciano J, Siliciano R . Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol. 2005; 304:3-15. DOI: 10.1385/1-59259-907-9:003. View

10.

Persaud D, Gay H, Ziemniak C, Chen Y, Piatak Jr M, Chun T . Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013; 369(19):1828-35. PMC: 3954754. DOI: 10.1056/NEJMoa1302976. View

11.

Ho Y, Shan L, Hosmane N, Wang J, Laskey S, Rosenbloom D . Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013; 155(3):540-51. PMC: 3896327. DOI: 10.1016/j.cell.2013.09.020. View

12.

Debaisieux S, Rayne F, Yezid H, Beaumelle B . The ins and outs of HIV-1 Tat. Traffic. 2011; 13(3):355-63. DOI: 10.1111/j.1600-0854.2011.01286.x. View

13.

Pasternak A, Adema K, Bakker M, Jurriaans S, Berkhout B, Cornelissen M . Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol. 2008; 46(7):2206-11. PMC: 2446885. DOI: 10.1128/JCM.00055-08. View

14.

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8. DOI: 10.1056/NEJMoa0802905. View

15.

Fazekas de St Groth . The evaluation of limiting dilution assays. J Immunol Methods. 1982; 49(2):R11-23. DOI: 10.1016/0022-1759(82)90269-1. View

16.

Weinberger L, Burnett J, Toettcher J, Arkin A, Schaffer D . Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell. 2005; 122(2):169-82. DOI: 10.1016/j.cell.2005.06.006. View

17.

PARKER R . STATISTICAL STUDIES OF THE NATURE OF THE INFECTIOUS UNIT OF VACCINE VIRUS. J Exp Med. 2009; 67(5):725-38. PMC: 2133630. DOI: 10.1084/jem.67.5.725. View

18.

SCHWERDT C, Fogh J . The ratio of physical particles per infectious unit observed for poliomyelitis viruses. Virology. 1957; 4(1):41-52. DOI: 10.1016/0042-6822(57)90042-9. View

19.

Chakraborty A, Das J . Pairing computation with experimentation: a powerful coupling for understanding T cell signalling. Nat Rev Immunol. 2009; 10(1):59-71. DOI: 10.1038/nri2688. View

20.

Myers L, McQuay L, Hollinger F . Dilution assay statistics. J Clin Microbiol. 1994; 32(3):732-9. PMC: 263116. DOI: 10.1128/jcm.32.3.732-739.1994. View